JS212 for Injection

DRUG4 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Huan Zhou

Conditions

Advanced Lung CancerAdvanced Malignant Solid TumorsAdvanced Malignant Solid TumoursNSCLC Harboring EGFR Mutations

Phase 1

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

RecruitingNCT06888830

Shanghai Junshi Bioscience Co., Ltd.Advanced Malignant Solid Tumours

Start: 2025-04-11End: 2028-12-31Target: 374Updated: 2026-07-08

Phase 2

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

RecruitingNCT07309276

Shanghai Junshi Bioscience Co., Ltd.Advanced Lung Cancer

Start: 2026-01-23End: 2028-11-11Target: 864Updated: 2026-05-18

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

RecruitingNCT07480733

Shanghai Junshi Bioscience Co., Ltd.Advanced Malignant Solid Tumors

Start: 2026-04-23End: 2028-11-11Target: 410Updated: 2026-05-29

Unknown Phase

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

Not yet recruitingNCT07714304

Huan ZhouNSCLC Harboring EGFR Mutations

Start: 2026-07-13End: 2029-07-23Target: 20Updated: 2026-07-20

Related Papers

Abstract CT128: Preliminary results from a first-in-human phase I/II study of JS212, an EGFR/HER3-targeted bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors

Cancer Research2026-04-17